Compounds > cilazapril, anhydrous
Page last updated: 2024-08-24

cilazapril, anhydrous and Metabolic Syndrome

cilazapril, anhydrous has been researched along with Metabolic Syndrome in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ban, Dj; Luo, R; Tian, F; Wu, Y; Zhao, Z1

Other Studies

1 other study(ies) available for cilazapril, anhydrous and Metabolic Syndrome

ArticleYear
Blockade of the RAS increases plasma adiponectin in subjects with metabolic syndrome and enhances differentiation and adiponectin expression of human preadipocytes.
    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2010, Volume: 118, Issue:4

    Topics: Adipocytes; Adiponectin; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Cell Differentiation; Cilazapril; Female; Humans; Male; Metabolic Syndrome; Radioimmunoassay; Regression Analysis; Renin-Angiotensin System; Reverse Transcriptase Polymerase Chain Reaction; Statistics, Nonparametric; Tetrazoles; Treatment Outcome

2010